NASDAQ:SAGE Sage Therapeutics - SAGE Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sage Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $41.91 -1.83 (-4.18%) (As of 03/30/2023 04:00 PM ET) Add Compare Share Share Today's Range$41.90▼$43.9750-Day Range$39.56▼$46.5752-Week Range$27.36▼$49.56Volume366,535 shsAverage Volume511,642 shsMarket Capitalization$2.50 billionP/E RatioN/ADividend YieldN/APrice Target$51.14 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Sage Therapeutics MarketRank™ ForecastAnalyst RatingHold2.31 Rating ScoreUpside/Downside21.1% Upside$51.14 Price TargetShort InterestBearish9.66% of Float Sold ShortDividend StrengthN/ASustainability-1.37Upright™ Environmental ScoreNews Sentiment0.33Based on 4 Articles This WeekInsider TradingSelling Shares$519,394 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($8.11) to ($7.56) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.07 out of 5 starsMedical Sector440th out of 999 stocksPharmaceutical Preparations Industry204th out of 489 stocks 3.2 Analyst's Opinion Consensus RatingSage Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.31, and is based on 4 buy ratings, 9 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $51.14, Sage Therapeutics has a forecasted upside of 21.1% from its current price of $42.24.Amount of Analyst CoverageSage Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.66% of the float of Sage Therapeutics has been sold short.Short Interest Ratio / Days to CoverSage Therapeutics has a short interest ratio ("days to cover") of 10, which indicates bearish sentiment.Change versus previous monthShort interest in Sage Therapeutics has recently decreased by 4.82%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldSage Therapeutics does not currently pay a dividend.Dividend GrowthSage Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSage Therapeutics has received a 72.37% net impact score from Upright. The largest positive contribution comes from its "Mental diseases" impact, which is driven by its "Antidepressants" and "Clinical research services for mental health" products. See details.Environmental SustainabilityThe Environmental Impact score for Sage Therapeutics is -1.37. Previous Next 1.8 News and Social Media Coverage News SentimentSage Therapeutics has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Sage Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 11 people have searched for SAGE on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Sage Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sage Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $519,394.00 in company stock.Percentage Held by InsidersOnly 4.80% of the stock of Sage Therapeutics is held by insiders.Percentage Held by Institutions85.60% of the stock of Sage Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Sage Therapeutics are expected to grow in the coming year, from ($8.11) to ($7.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sage Therapeutics is -4.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sage Therapeutics is -4.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSage Therapeutics has a P/B Ratio of 2.01. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Sage Therapeutics (NASDAQ:SAGE) StockSAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel medicines. It targets diseases and disorders of the brain with three key focus areas: depression, neurology, and neuropsychiatry. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010, and is headquartered in Cambridge, MA.Read More Receive SAGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sage Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SAGE Stock News HeadlinesMarch 30, 2023 | marketwatch.comEssential Tremor Treatment Market Trends, Industry Demand and Scope, Top Players Analysis, Forecast 2023 - 2031March 29, 2023 | marketwatch.comPostpartum Depression Treatment Market Top Players By 2031March 30, 2023 | Weiss Ratings (Ad)Bank Accounts: Frozen!In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!March 26, 2023 | marketwatch.comMild Cognitive Impairment Therapeutic Market By 2031March 22, 2023 | marketwatch.comEssential Tremor Treatment Market Size by 2031March 22, 2023 | marketwatch.comEssential Tremor Treatment Market Key Players and Forecast till 2028March 22, 2023 | finance.yahoo.comSage Therapeutics to Present at the Stifel 2023 CNS DaysMarch 16, 2023 | finance.yahoo.comSage Therapeutics Appoints Jessica Federer to Board of DirectorsMarch 30, 2023 | Stansberry Research (Ad)The gold catalyst we’ve waited forIf you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK. March 13, 2023 | msn.comAnalyst Creates Bullish Pitch For Sage Therapeutics Around Greater Enthusiasm For Its Depression Drug, ZuranoloneMarch 9, 2023 | msn.comWhat 5 Analyst Ratings Have To Say About Sage TherapeuticsMarch 8, 2023 | finance.yahoo.comWe're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash WiselyMarch 8, 2023 | finance.yahoo.comSage Therapeutics and Biogen Share Update on FDA Advisory Committee for ZuranoloneMarch 1, 2023 | finance.yahoo.comSage Therapeutics to Present at the Cowen 43rd Annual Health Care ConferenceFebruary 22, 2023 | finance.yahoo.comSage Therapeutics Announces European Medicines Agency Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s DiseaseFebruary 17, 2023 | markets.businessinsider.comBank of America Securities Keeps Their Buy Rating on SAGE Therapeutics (SAGE)February 17, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: MacroGenics (MGNX) and SAGE Therapeutics (SAGE)February 17, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Biogen (BIIB), SAGE Therapeutics (SAGE) and Karyopharm Therapeutics (KPTI)February 16, 2023 | marketwatch.comPostpartum Depression Therapeutics Market is Booming in Near Future 2023-2028 with Top Countries DataFebruary 16, 2023 | finance.yahoo.comSage Therapeutics, Inc. (SAGE) Reports Q4 Loss, Tops Revenue EstimatesFebruary 15, 2023 | marketwatch.comEssential Tremor Treatment Market Growth, Business Overview and Forecast to 2028February 13, 2023 | marketwatch.comEssential Tremor Treatment Market Size in 2023 | NEWEST REPORT | Touch New Level in Forthcoming year till 2028February 13, 2023 | msn.comWhat To Know Regarding A Potential FDA Approved Drug For Postpartum DepressionFebruary 13, 2023 | msn.comThe top doctor at a $2.7 billion pharma company developing a new depression drug says we may be 'on the cusp' of a new wave of mental-health treatmentsFebruary 7, 2023 | msn.comFirst pill for postpartum depression could be approved by August: FDAFebruary 7, 2023 | finance.yahoo.comSage and Biogen's NDA for Depression Drug Gets Priority ReviewFebruary 7, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Omeros (OMER) and SAGE Therapeutics (SAGE)See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SAGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sage Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SAGE Company Calendar Last Earnings2/16/2023Today3/30/2023Next Earnings (Estimated)5/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SAGE CUSIPN/A CIK1597553 Webwww.sagerx.com Phone(617) 299-8380Fax617-299-8379Employees471Year FoundedN/APrice Target and Rating Average Stock Price Forecast$51.14 High Stock Price Forecast$73.00 Low Stock Price Forecast$37.00 Forecasted Upside/Downside+21.1%Consensus RatingHold Rating Score (0-4)2.31 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($8.98) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-532,780,000.00 Net Margins-6,930.97% Pretax Margin-6,931.88% Return on Equity-37.03% Return on Assets-34.65% Debt Debt-to-Equity RatioN/A Current Ratio13.47 Quick Ratio13.47 Sales & Book Value Annual Sales$7.69 million Price / Sales328.03 Cash FlowN/A Price / Cash FlowN/A Book Value$21.05 per share Price / Book2.01Miscellaneous Outstanding Shares59,720,000Free Float56,852,000Market Cap$2.52 billion OptionableOptionable Beta1.15 Key ExecutivesBarry E. GreenePresident, Chief Executive Officer & DirectorKimi E. IguchiChief Financial & Accounting OfficerAl RobichaudChief Scientific OfficerAmy SchacterleSenior VP-Research & Development StrategyMatt LasmanisChief Technology & Innovation OfficerKey CompetitorsMyovant SciencesNYSE:MYOVProthenaNASDAQ:PRTARevance TherapeuticsNASDAQ:RVNCArrowhead PharmaceuticalsNASDAQ:ARWRBlueprint MedicinesNASDAQ:BPMCView All CompetitorsInsiders & InstitutionsNeo Ivy Capital ManagementBought 5,094 shares on 3/27/2023Ownership: 0.009%Teachers Retirement System of The State of KentuckySold 5,031 shares on 2/22/2023Ownership: 0.122%AQR Capital Management LLCSold 3,962 shares on 2/15/2023Ownership: 0.026%Schonfeld Strategic Advisors LLCBought 5,668 shares on 2/15/2023Ownership: 0.025%E Fund Management Co. Ltd.Sold 2,753 shares on 2/15/2023Ownership: 0.014%View All Insider TransactionsView All Institutional Transactions SAGE Stock - Frequently Asked Questions Should I buy or sell Sage Therapeutics stock right now? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sage Therapeutics in the last year. There are currently 9 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" SAGE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SAGE, but not buy additional shares or sell existing shares. View SAGE analyst ratings or view top-rated stocks. What is Sage Therapeutics' stock price forecast for 2023? 13 equities research analysts have issued 1-year target prices for Sage Therapeutics' shares. Their SAGE share price forecasts range from $37.00 to $73.00. On average, they predict the company's share price to reach $51.14 in the next twelve months. This suggests a possible upside of 21.4% from the stock's current price. View analysts price targets for SAGE or view top-rated stocks among Wall Street analysts. How have SAGE shares performed in 2023? Sage Therapeutics' stock was trading at $38.14 at the beginning of the year. Since then, SAGE stock has increased by 10.5% and is now trading at $42.14. View the best growth stocks for 2023 here. When is Sage Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023. View our SAGE earnings forecast. How were Sage Therapeutics' earnings last quarter? Sage Therapeutics, Inc. (NASDAQ:SAGE) released its earnings results on Thursday, February, 16th. The biopharmaceutical company reported ($2.47) EPS for the quarter, missing analysts' consensus estimates of ($2.37) by $0.10. The biopharmaceutical company earned $2.87 million during the quarter, compared to the consensus estimate of $1.94 million. Sage Therapeutics had a negative trailing twelve-month return on equity of 37.03% and a negative net margin of 6,930.97%. The firm's quarterly revenue was up 74.7% compared to the same quarter last year. During the same period in the prior year, the firm posted ($2.12) earnings per share. What ETFs hold Sage Therapeutics' stock? ETFs with the largest weight of Sage Therapeutics (NASDAQ:SAGE) stock in their portfolio include Psyk Etf (PSYK), AdvisorShares Psychedelics ETF (PSIL), Virtus LifeSci Biotech Products ETF (BBP), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC) and WisdomTree U.S. SmallCap Fund (EES). What other stocks do shareholders of Sage Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sage Therapeutics investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Netflix (NFLX), Roku (ROKU), QUALCOMM (QCOM) and Bristol-Myers Squibb (BMY). What is Sage Therapeutics' stock symbol? Sage Therapeutics trades on the NASDAQ under the ticker symbol "SAGE." Who are Sage Therapeutics' major shareholders? Sage Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (3.19%), JPMorgan Chase & Co. (2.37%), Dimensional Fund Advisors LP (2.22%), Geode Capital Management LLC (1.69%), Marshall Wace LLP (1.57%) and The Manufacturers Life Insurance Company (1.05%). Insiders that own company stock include Barry E Greene, Barry E Greene, George Golumbeski, James M Frates and Jeffrey M Jonas. View institutional ownership trends. How do I buy shares of Sage Therapeutics? Shares of SAGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Sage Therapeutics' stock price today? One share of SAGE stock can currently be purchased for approximately $42.14. How much money does Sage Therapeutics make? Sage Therapeutics (NASDAQ:SAGE) has a market capitalization of $2.52 billion and generates $7.69 million in revenue each year. The biopharmaceutical company earns $-532,780,000.00 in net income (profit) each year or ($8.98) on an earnings per share basis. How many employees does Sage Therapeutics have? The company employs 471 workers across the globe. How can I contact Sage Therapeutics? Sage Therapeutics' mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The official website for the company is www.sagerx.com. The biopharmaceutical company can be reached via phone at (617) 299-8380, via email at ir@sagerx.com, or via fax at 617-299-8379. This page (NASDAQ:SAGE) was last updated on 3/30/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.